There were 53% of the subjects of 1288 rectal cancer patients who showed KRAS mutation, and overexpression of HER2 was shown in 53.6% of those with mutated KRAS, with a P-value showing no significant association. The gene discussed is ERBB2; the disease is rectal cancer.